ALMR vs BIO
ALMR: Alamar Biosciences is a commercial-stage proteomics company providing ultra-sensitive protein biomarker detection instruments and consumables for research and diagnostics. BIO: A multinational life science and clinical diagnostics company providing research tools, diagnostic test systems, and consumables to laboratories and biopharmaceutical manufacturers worldwide.
Side-by-side fundamentals
| Metric | ALMR | BIO | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $25.12 | $305.96 | |
| Market cap as of 2026-07-23 | $1.8B | $8.2B | |
| P/E as of 2026-07-23 | n/a | 48.82 | |
| Net margin as of 2026-07-23 | -40.2% | +6.5% | BIO higher |
| Gross margin as of 2026-07-23 | +56.2% | +51.8% | ALMR higher |
| Operating margin as of 2026-07-23 | -42.2% | +2.0% | BIO higher |
| ROE as of 2026-07-23 | -39.2% | +2.4% | BIO higher |
| ROA as of 2026-07-23 | -21.3% | +1.7% | BIO higher |
| Debt / equity as of 2026-07-23 | 1.32 | 0.18 | BIO lower |
| Revenue growth (YoY) as of 2026-07-23 | n/a | +1.9% | |
| Revenue CAGR (3y) SEC XBRL | n/a | -2.7% | |
| Beta as of 2026-07-23 | -1.39 | 1.06 | |
| 1-year return as of 2026-07-22 close | +14.3% | +24.6% | BIO higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.